BiomX Inc. (NYSEAMERICAN:PHGE) Sees Significant Growth in Short Interest

BiomX Inc. (NYSEAMERICAN:PHGE) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 442,700 shares, an increase of 553.9% from the February 29th total of 67,700 shares. Based on an average daily trading volume, of 2,550,000 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $2.00 price target on shares of BiomX in a research report on Thursday, March 7th.

Institutional Trading of BiomX

A hedge fund recently bought a new stake in BiomX stock. 8VC GP I LLC purchased a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,086,191 shares of the company’s stock, valued at approximately $304,000. BiomX makes up 0.3% of 8VC GP I LLC’s holdings, making the stock its 3rd largest holding. 8VC GP I LLC owned 2.36% of BiomX at the end of the most recent reporting period. Institutional investors and hedge funds own 40.57% of the company’s stock.

BiomX Trading Up 26.4 %

PHGE stock traded up $0.09 during trading on Thursday, hitting $0.45. The company had a trading volume of 451,927 shares, compared to its average volume of 2,679,349. BiomX has a 1-year low of $0.19 and a 1-year high of $0.86. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.98 and a current ratio of 1.98.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).